CYCCP
Closed
Cyclacel Pharmaceuticals Inc
5.28
-0.21 (-3.83%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 5.49
Day's Range: 5.25 - 5.79
Send
sign up or login to leave a comment!
When Written:
15.51
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on the development of innovative therapies for the treatment of cancer and other serious diseases. The company's lead product candidate is sapacitabine, an orally available nucleoside analogue that has demonstrated promising results in clinical trials for the treatment of various types of cancer, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and solid tumors.
In addition to sapacitabine, Cyclacel Pharmaceuticals is also developing other product candidates, including CYC065, a cyclin-dependent kinase (CDK) inhibitor that is being evaluated in clinical trials for the treatment of solid tumors, and CYC140, a polo-like kinase (PLK) inhibitor that is being developed for the treatment of cancer.
The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol CYCC.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
In addition to sapacitabine, Cyclacel Pharmaceuticals is also developing other product candidates, including CYC065, a cyclin-dependent kinase (CDK) inhibitor that is being evaluated in clinical trials for the treatment of solid tumors, and CYC140, a polo-like kinase (PLK) inhibitor that is being developed for the treatment of cancer.
The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol CYCC.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








